Image Place holder

Theresa Ann Boyle, MD, PhD

Academic Rank: Assistant Member

Overview

Dr. Boyle's clinical work focuses on interpretation of molecular results to guide patient therapy. She also acts as a consult for both physicians and patients to improve their understanding of molecular results.


Discipline

    • Anatomic Pathology
    • Tumor Biology
    • Chemical Biology and Molecular Medicine Program

Education & Training

Board Certification:

  • Anatomic Pathology & Clinical Pathology

Fellowship:

  • Howard University College of Medicine, MD -
  • University of Colorado Health Sciences Center, PhD - Human Medical Genetics
  • University of Colorado at Denver, Resident - Clinical and Anatomic Pathology
  • Stanford University, Palo Alto, Fellow - Molecular Genetic Patholoy
Research

Research Interests: To develop assays, such as the proximity ligation assay (PLA) to visualize cancer signaling pathway response to drug therapy. To investigate tumor biomarkers that predicts response to therapy, such as those that identify patients with tumors that will most likely to respond to immunotherapy. To develop resources, such as tumor microarrays (TMAs), to facilitate research and clinical assay development.

Publications

  • Gray JE, Chiappori A, Williams CC, Tanvetyanon T, Haura EB, Creelan BC, Kim J, Boyle TA, Pinder-Schenck M, Khalil F, Altiok S, Devane R, Noyes D, Mediavilla-Varela M, Smilee R, Hopewell EL, Kelley L, Antonia SJ. A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. Cancer Immunol Immun. 2018 Sep. Pubmedid: 30209589. Pmcid: PMC6244998.
  • Farago AF, Taylor MS, Doebele RC, Zhu VW, Kummar S, Spira AI, Boyle TA, Haura EB, Arcila ME, Benayed R, Aisner DL, Horick NK, Lennerz JK, Le LP, Iafrate AJ, Ou SI, Shaw AT, Mino-Kenudson M, Drilon A. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an Gene Fusion. JCO Precis Oncol. 2018 Sep;2018. Pubmedid: 30215037. Pmcid: PMC6132056.
  • Le X, Puri S, Negrao MV, Nilsson M, Robichaux JP, Boyle TA, Hicks JK, Lovinger K, Roarty EB, Rinsurongkawong W, Tang M, Sun H, Elamin YY, Lacerda L, Lewis J, Lee JJ, Roth JA, Swisher SG, Zhang J, William WN, Glisson BS, Papadimitrakopoulou VA, Gray JE, Heymach JV. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in -Mutant NSCLC. Clin Cancer Res. 2018 Sep. Pubmedid: 30228210.
  • Ng TL, Yu H, Smith DE, Boyle TA, York ER, Leedy S, Gao D, Aisner DL, Van Bokhoven A, Heasley LE, Hirsch FR, Camidge DR. Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. Clin Lung Cancer. 2018 Sep. Pubmedid: 30297175.
  • Pérez-Morales J, Mejías-Morales D, Rivera-Rivera S, González-Flores J, González-Loperena M, Cordero-Báez FY, Pedreira-García WM, Chardón-Colón C, Cabán-Rivera J, Cress WD, Gordian ER, Muñoz-Antonia T, Cabrera-Ríos M, Isidro A, Coppola D, Rosa M, Boyle TA, Izumi V, Koomen JM, Santiago-Cardona PG. Hyper-phosphorylation of Rb S249 together with CDK5R2/p39 overexpression are associated with impaired cell adhesion and epithelial-to-mesenchymal transition: Implications as a potential lung cancer grading and staging biomarker. PLoS One. 2018 Nov;13(11):e0207483. Pubmedid: 30452490.
  • Hicks JK, Boyle T, Albacker LA, Madison R, Frampton G, Creelan BC. Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion. J Thorac Oncol. 2018 Aug;13(8):e148-e150. Pubmedid: 30049378.
  • Quinn G, Pentz RD, Muñoz-Antonia T, Boyle TA, Schabath MB, Pratt C, Shaffer A, Duarte L, Bowman-Curci M, Antonia S, Chiappori A, Creelan B, Gray JE, Williams C, Haura E. Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program. Patient Educ Couns. 2018 Apr;101(4):703-710. Pubmedid: 29195718. Pmcid: PMC5878993.
  • Hicks JK, Saller J, Wang E, Boyle T, Gray JE. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results. Lung Cancer. 2017 Sep;111:135-138. Pubmedid: 28838384.
  • Smith MA, Licata T, Lakhani A, Varella-Garcia M, Schildhaus HU, Vuaroqueaux V, Halmos B, Borczuk A, Chen YA, Creelan BC, Boyle TA, Haura EB. MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors. Clin Cancer Res. 2017 Nov;23(22):7084-7096. Pubmedid: 28855353. Pmcid: PMC5833309.
  • Kuenzi BM, Remsing Rix LL, Stewart PA, Fang B, Kinose F, Bryant AT, Boyle TA, Koomen JM, Haura EB, Rix U. Polypharmacology-based ceritinib repurposing using integrated functional proteomics. Nat Chem Biol. 2017 Dec;13(12):1222-1231. Pubmedid: 28991240. Pmcid: PMC5909815.
  • Yu H, Batenchuk C, Badzio A, Boyle TA, Czapiewski P, Chan DC, Lu X, Gao D, Ellison K, Kowalewski AA, Rivard CJ, Dziadziuszko R, Zhou C, Hussein M, Richards D, Wilks S, Monte M, Edenfield W, Goldschmidt J, Page R, Ulrich B, Waterhouse D, Close S, Jassem J, Kulig K, Hirsch FR. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. J Thorac Oncol. 2017 01;12(1):110-120. Pubmedid: 27639678. Pmcid: PMC5353355.
  • Bishop AC, Boyle TA. The Role of Safety Culture in Influencing Provider Perceptions of Patient Safety. J Patient Saf. 2016 Dec;12(4):204-209. Pubmedid: 24618647.
  • Tanvetyanon T, Boyle TA. Clinical implications of genetic heterogeneity in multifocal pulmonary adenocarcinomas. J Thorac Dis. 2016 Dec;8(12):E1734-E1738. Pubmedid: 28149626. Pmcid: PMC5227290.
  • Yu H, Boyle TA, Zhou C, Rimm D, Hirsch FR. PD-L1 Expression in Lung Cancer. J Thorac Oncol. 2016 07;11(7):964-975. Pubmedid: 27117833. Pmcid: PMC5353357.
  • Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, Wynes M, Miller VA, Lipson D, Palmer GA, Ali SM, Dekel S, Brenner R, Bunn PA, Peled N. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist. 2015 Mar;20(3):316-322. Pubmedid: 25721120. Pmcid: PMC4350802.
  • Boyle TA, Masago K, Ellison KE, Yatabe Y, Hirsch FR. ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin Lung Cancer. 2015 Mar;16(2):106-111. Pubmedid: 25467930. Pmcid: PMC4770803.
  • Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, Dziadziuszko R, Jassem J, Varella-Garcia M, Heasley LE, Kowalewski AA, Ellison K, Chen G, Zhou C, Hirsch FR. Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul;10(7):1083-1090. Pubmedid: 26020126. Pmcid: PMC4467588.
  • Bishop AC, Baker GR, Boyle TA, MacKinnon NJ. Using the Health Belief Model to explain patient involvement in patient safety. Health Expect. 2015 Dec;18(6):3019-3033. Pubmedid: 25303173. Pmcid: PMC5810747.
  • Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, Zhou C, Camidge DR. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol. 2014 Mar;9(3):e21-e23. Pubmedid: 24518095. Pmcid: PMC4117236.
  • Aherne CM, Collins CB, Masterson JC, Tizzano M, Boyle TA, Westrich JA, Parnes JA, Furuta GT, Rivera-Nieves J, Eltzschig HK. Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis. Gut. 2012 May;61(5):695-705. Pubmedid: 21813473. Pmcid: PMC3322588.
  • Baschal EE, Jasinski JM, Boyle TA, Fain PR, Eisenbarth GS, Siebert JC. Congruence as a measurement of extended haplotype structure across the genome. J Transl Med. 2012 Feb;10:32. Pubmedid: 22369243. Pmcid: PMC3310717.
  • Baschal EE, Sarkar SA, Boyle TA, Siebert JC, Jasinski JM, Grabek KR, Armstrong TK, Babu SR, Fain PR, Steck AK, Rewers MJ, Eisenbarth GS. Replication and further characterization of a Type 1 diabetes-associated locus at the telomeric end of the major histocompatibility complex. J Diabetes. 2011 Sep;3(3):238-247. Pubmedid: 21631897. Pmcid: PMC3610173.
  • Symonds JM, Ohm AM, Carter CJ, Heasley LE, Boyle TA, Franklin WA, Reyland ME. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors. Cancer Res. 2011 Mar;71(6):2087-2097. Pubmedid: 21335545. Pmcid: PMC3271733.